SEC	Form	4
-----	------	---

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person [*] White Jonathan (Last) (First) (Middle) 400 WOOD ROAD						2. Issuer Name and Ticker or Trading Symbol <u>HAEMONETICS CORP</u> [HAE] 3. Date of Earliest Transaction (Month/Day/Year) 02/07/2014									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) Chief Science and Technology					wner specify
(Street) BRAINTREE MA 02184						4. If Amendment, Date of Original Filed (Month/Day/Year)									 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting 					ו
(City)	(Sta		Zip)													Person				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					saction	ear)	2A. Dee Executi if any (Month/	e, Trans Code	-	on	4. Securities Disposed Of	Acquired	(A) or	or 5. Amo and 5) Securit Benefic		.	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code V		Amount	Amount (A) or (D)		9	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common S	Stock			02/0	07/2014		<u> </u>		S	T		700	D	\$38.66		26,346		D		
Common S	Stock			02/0	/07/2014				S			315	D	\$38.672		26,031		D		
Common S	Stock				7/201							865			8.66	25,166		56 D		
		-										osed of, o onvertible				wned				
1. Title of Derivative Security (Instr. 3) 2. 3. Transaction Date 3A. Deemed Execution D (Month/Day/Year) 1. Title of Derivative Security 2. 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution D if any (Month/Day.		Date,	4. Transactio Code (Instr		on of		Expiratio	6. Date Exercisal Expiration Date (Month/Day/Year		of Securities		ies g Secu		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	ve Ow ies For ially Dir or ng (I) ed ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	ble		xpiration ate	Title	Amo or Num of Shar	ber					
Non- Qualified Stock Option (right to buy)	\$26.47								10/27/20	10 ⁽¹⁾	:	10/27/2016	Common Stock	24,4	484		24,48	34	D	
Non- Qualified Stock Option (right to buy)	\$27.495								10/27/20	1 ⁽¹⁾	:	10/27/2017	Common Stock	30,	776		30,77	76	D	
Non- Qualified Stock Option (right to buy)	\$30.025								01/28/20	10 ⁽¹⁾		01/28/2016	Common Stock	35,2	282		35,28	32	D	
Non- Qualified Stock Option (right to buy)	\$30.67								10/25/20	12 ⁽¹⁾	:	10/25/2018	Common Stock	35,	130		35,13	80	D	
Non- Qualified Stock Option (right to buy)	\$33.925								07/20/20	12 ⁽¹⁾	(07/20/2018	Common Stock	27,9	948		27,94	18	D	
Non- Qualified Stock Option (right to buy)	\$39.055								10/24/20	1 ³⁽¹⁾		10/24/2019	Common Stock	32,	192		32,19	02	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Code (Instr. 8) Code (Instr. 9) Code (Instr.		6. Date Exerci Expiration Dat (Month/Day/Ye	e	7. Title an of Securit Underlyin Derivative (Instr. 3 ar	es g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$41.66							10/23/2014 ⁽¹⁾	10/23/2019	Common Stock	28,523		28,523	D	
Performance Shares	\$0.0							03/31/2017 ⁽²⁾	12/31/2017 ⁽²⁾	Common Stock	25,000		25,000	D	

Explanation of Responses:

1. Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

2. Market Share Units repersent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).

By: Alexander Steffan For: Jonathan White

02/10/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.